An investigation on the effect of memantine on children with autistic spectrum disorder

Evaluation of the efficacy of memantine in improvement of behavioral disorders and electroencephalographic findings in children with autistic spectrum disorder aged 4-12 years old

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211118053097N1

Enrollment

Registered

2022-03-26

Start date

2022-04-04

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients diagnosed with ASD. Autistic disorder

Interventions

Intervention 1: Intervention group: group 1 would receive risperidone with 0.25 mg/ daily initiation dose for under 20kg weight and 0.5mg/daily for above 20kg. they would also receive memantine (? Osv

Eligibility

Sex/Gender

All

Age

4 Years to 12 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with ASD according to DSM 5 Patients with no previous history of epilepsy and/or abnormal electroencephalography Patients aged between 4 to 12 years old

Exclusion criteria

Exclusion criteria: Intolerance to Memantine Patients and/or their caregiver’s disinclination to continuing with trail

Design outcomes

Primary

Measure	Time frame
Electroencephalography analysis. Timepoint: Before the treatment and 10 weeks after treatment onset. Method of measurement: Using the Electroencephalograph and analysis of activities.;ABC questionnaire (measuring cognitive activity). Timepoint: Before the treatment and 10 weeks after treatment onset. Method of measurement: Filling ABC autism questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarjes Raja-beheshti

Shiraz University of Medical Sciences

Narjesrb@gmail.com+98 71 3212 7000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026